World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
75
Citations
52206
World Ranking
18950
National Ranking
1712

Overview

Philip Home is affiliated with Newcastle University in the United Kingdom and has contributed extensively to the field of Medicine, with a particular focus on Endocrinology, Diabetes, and Metabolism.

The scientist's research spans several subfields including:

  • Endocrinology, Diabetes and Metabolism
  • Molecular Biology
  • Cardiology and Cardiovascular Medicine
  • Surgery
  • Pharmacology

Main topics covered in their work include:

  • Diabetes Treatment and Management
  • Diabetes Management and Research
  • Metabolism, Diabetes, and Cancer
  • Pancreatic function and diabetes
  • Cardiovascular Function and Risk Factors
  • Pharmacology and Obesity Treatment
  • COVID-19 Clinical Research Studies

Philip Home has published numerous papers, some of the recent notable ones are:

  • Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure (2020), published in New England Journal of Medicine
  • Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease (2020), published in New England Journal of Medicine
  • Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes (2021), published in Diabetes Care
  • Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial (2020), published in The Lancet Neurology
  • The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial (2020), published in The Lancet Diabetes & Endocrinology

The scientist often collaborates with frequent co-authors including:

  • Hertzel C. Gerstein
  • Lawrence A. Leiter
  • Jeffrey L. Probstfield
  • Rafael Díaz
  • Mark Lakshmanan

Philip Home's work appears regularly in several publication venues, with repeated contributions to:

  • Diabetes Care
  • UNC Libraries
  • Diabetes
  • Diabetes Obesity and Metabolism
  • Cardiovascular Diabetology

Best Publications

  • Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

    R C Turner;R R Holman;C A Cull;I M Stratton

  • European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice.

    Guy De Backer;Ettore Ambrosioni;Knut Borch-Johnsen;Carlos Brotons

  • Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

    Philip D. Home;Stuart J. Pocock;Henning Beck-Nielsen;Paula S. Curtis

  • Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.

    Philip D. Home;Stuart J. Pocock;Henning Beck-Nielsen;Ramón Gomis

  • A desktop guide to Type 2 diabetes mellitus

    M. Aguilar;K. G.M.M. Alberti;S. A. Amiel;J. Azzopardi

  • A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naïve People With Type 2 Diabetes

    Kjeld Hermansen;Melanie Davies;Taudeusz Derezinski;Gabrielle Martinez Ravn

  • A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes

    J. Rosenstock;M. Davies;P. D. Home;J. Larsen

  • Principles for National and Regional Guidelines on Cardiovascular Disease Prevention A Scientific Statement From the World Heart and Stroke Forum

    Sidney C. Smith;Rod Jackson;Thomas A. Pearson;Valentin Fuster

  • The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease

    Latika Sibal;Sharad C Agarwal;Philip D Home;Rainer H Boger

  • New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1)

    Matthew C. Riddle;Geremia B. Bolli;Monika Ziemen;Isabel Muehlen-Bartmer

  • New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3)

    G B Bolli;M C Riddle;R M Bergenstal;M Ziemen

  • Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patients.

    B. O. Boehm;P. D. Home;C. Behrend;N. M. Kamp

  • Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin A 24-week, randomized, placebo-controlled comparison (GetGoal-l)

    Matthew C. Riddle;Ronnie Aronson;Philip Home;Michel Marre

  • Guidelines for the treatment and management of new-onset diabetes after transplantation

    Alan Wilkinson;Jaime Davidson;Francesco Dotta;Philip D Home

  • Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial

    P. D. Home;A. Lindholm;A. Riis

  • Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group.

    P D Home;A Lindholm;B Hylleberg;P Round

  • Insulin Detemir Offers Improved Glycemic Control Compared With NPH Insulin in People With Type 1 Diabetes: A randomized clinical trial.

    Philip Home;Paul Anthony Bartley;David Russell-Jones;Helene Hanaire-Broutin

  • Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial

    Michel Komajda;John J.V. McMurray;Henning Beck-Nielsen;Ramon Gomis

  • 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

    F Cosentino;P J Grant;V Aboyans;C J Bailey

  • Advances in the Science, Treatment, and Prevention of the Disease of Obesity: Reflections From a Diabetes Care Editors' Expert Forum.

    William T. Cefalu;George A. Bray;Philip D. Home;W. Timothy Garvey

Frequent Co-Authors

Geremia B. Bolli
Geremia B. Bolli University of Perugia
Nick Freemantle
Nick Freemantle University College London
Michel Marre
Michel Marre Université Paris Cité
Nicolas Danchin
Nicolas Danchin Université Paris Cité
Hannele Yki-Järvinen
Hannele Yki-Järvinen University of Helsinki
Henning Beck-Nielsen
Henning Beck-Nielsen Odense University Hospital
Stuart J. Pocock
Stuart J. Pocock London School of Hygiene & Tropical Medicine
Ryuzo Kawamori
Ryuzo Kawamori Juntendo University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn't always require a traditional path. Many students are now turning to online programs for greater flexibility and affordability. For those aiming to advance their nursing qualifications, the cheapest dnp programs can open doors to leadership and clinical specialist roles while allowing you to balance work and study.

If pharmacy is your passion, accredited pharmacy school online options make it possible to earn a doctorate without relocating or sacrificing current obligations.

For those interested in managing health data, pursuing a degree in health informatics is an excellent way to assemble skills at the intersection of healthcare and technology.

Alternatively, if you want to quickly enter the healthcare workforce, medical billing and coding online courses help you qualify for in-demand administrative careers.

These online options offer varied paths into healthcare, letting you fit your education around your life while preparing for rewarding roles.

Best Scientists Citing Philip Home

Trending Scientists

Recently Published Articles